A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Abstract Text:

J Marcusson,M Rother,B Kittner,M ,R J Smith,T Babic,V Folnegovic-Smalc,H J ,K H Labs,

Alzheimer's disease (AD) and vascular dementia (VaD) share several features such as overactivation of microglial cells, damage induced by free radicals, glutamate and calcium overload. Propentofylline (HWA 285) has shown beneficial effects on all of these common elements, thus favouring its use in both subtypes of dementia. In a multinational, randomized, 12-month, double-blind, parallel-group study 260 out-patients with mild to moderate AD or VaD received 300 mg propentofylline (n = 129) or placebo (n = 131) three times daily 1 h before meals. The efficacy was tested at four independent rater levels (physician, psychologist, relative and patient) with assessments covering three major domains of dementia (global function, cognitive function and activities of daily living). After 12 months, the total patient population showed statistically significant treatment differences in favour of propentofylline for the global measures of dementia (Gottfries-Bråne-Steen scale, GBS, p = 0.001; Clinical Global Impressions, CGI, item I: p = 0.004, item II: p = 0.072) as well as for the cognitive measures (Syndrome Short Test, SKT, p = 0.002) and Mini-Mental State Examination (p = 0.001). The activities of daily living also showed a significant treatment difference in favour of propentofylline (p = 0.002). No significant treatment differences were found for rating scales performed by the patients. At month 12, VaD patients showed treatment differences in favour of propentofylline for the GBS total score (p = 0.006), CGI item I (p = 0.004), GGI item II (p = 0.044) and SKT (p = 0.028). Treatment differences for AD patients were all in favour of propentofylline and reached statistical significance for the SKT (p = 0.018). Propentofylline showed a good safety profile with respect to adverse events, vital signs, ECG and laboratory changes.

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Publishing Authors By Initials

J Marcusson,M Rother,B Kittner,M ,RJ Smith,T Babic,V Folnegovic-Smalc,HJ ,KH Labs,

For similar heterocyclic compounds: alkaloids: xanthines research abstracts see: heterocyclic compounds: alkaloids: xanthines research

PUBMED ID PMID:

MEDLINE DATE: 1997 Sep-Oct

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Dementia and geriatric cognitive disorders

VOLUME: 8

Page Numbers: 320-8

Journal Abbreviation: Dement Geriatr Cogn Disord

ISSN: 1420-8008

DAY: 24

MONTH: 03

YEAR: 2008

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9705200

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Keywords Mesh Terms:

KEYWORDS: Xanthines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Information

Substance Name: propentofylline

Registry Number: 55242-55-2

Grant and Affiliation Information for A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.

AFFILIATION: Geriatric Clinic, University Hospital, Linköping (Sweden). Jan.Marcusson@ger.us.lio.se

Country: SWITZERLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Dement Geriatr Cogn Disord

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A 12-month, randomized, placebo-controlled trial of propentofylline HWA 285 in patients with dementia according to DSM III-R The European Propentofylline Study Group Related Publications

• A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.
• Clinical characteristics of roxatidine acetate: a review.
• Standard of care for hand trauma: where should we be going?
• [The value of Doppler spectral analysis for practical diagnosis]